5 research outputs found
A systematic literature review of cysteamine bitartrate in the treatment of nephropathic cystinosis
<p><b>Objectives:</b> To summarize available clinical evidence for cysteamine bitartrate preparations in the treatment of nephropathic cystinosis as identified through a systematic literature review (SLR).</p> <p><b>Methods:</b> We searched MEDLINE, MEDLINE In-Process and Embase using Ovid with a predefined search strategy through 19 January 2016. All publicly available clinical reports on the use of delayed-release (DR) cysteamine bitartrate (Procysbi<a href="#FN0001" target="_blank"><sup>1</sup></a>) or immediate-release (IR) cysteamine bitartrate (Cystagon<a href="#FN0002" target="_blank"><sup>2</sup></a>) in patients with cystinosis were included.</p> <p><b>Results:</b> We identified a total of 103 publications and 10 trial records. Of these, 9 studies describe DR cysteamine bitartrate (<i>n</i> = 267 patients), 42 describe IR cysteamine bitartrate (<i>n</i> = 1,427 patients) and in 53 studies the exact preparation was not specified (<i>n</i> = 906 patients). The vast majority of the studies used a non-randomized study design, with randomized clinical trials (RCTs) being scarce (1 study comparing DR and IR formulation) and case reports (<i>n</i> = 49) being the most common study design representing 47% of the total.</p> <p><b>Conclusion:</b> A substantial evidence base for cysteamine bitartrate in the treatment of nephropathic cystinosis was identified. However, the majority of the evidence was of relatively low quality, with evidence levels of 3 or 4.</p
Supplementary tables: Costs and outcomes of mobile cardiac outpatient telemetry monitoring post-transcatheter aortic valve replacement
These are peer-reviewed supplementary materials for the article 'Costs and outcomes of mobile cardiac outpatient telemetry monitoring post-transcatheter aortic valve replacement' published in the Journal of Comparative Effectiveness Research.Supplementary Table 1: CPT and ICD-10 CodesSupplementary Table 2: Propensity score adjusted revenue center costs for patients with MCOT monitoring versus non-MCOT monitoring post-TAVR procedureAim: To estimate the costs and outcomes of transcatheter aortic valve replacement (TAVR) recipients based on the use of mobile cardiac outpatient telemetry (MCOT) monitoring. Materials & methods: A retrospective database study was conducted to estimate costs, contribution margins (CMs), pacemaker insertions and other outcomes for patients undergoing TAVR procedures with MCOT monitoring postprocedure versus non-MCOT monitoring. Results: A total of 4164 patients were identified (283 MCOT monitoring and 3881 non-MCOT monitoring). The rate of pacemaker insertion following hospital discharge was higher in the MCOT cohort (6.6 MCOT vs 2.1% non-MCOT; p = 0.007). MCOT use was associated with lower costs and improved CMs of the index TAVR admission (costs: US43,289 non-MCOT; p = 0.003; CMs: US5177 non-MCOT; p = 0.047) with no difference through the subsequent 60-day period following discharge. Conclusion: MCOT for ambulatory cardiac monitoring post-TAVR discharge is associated with higher rates of pacemaker insertion, at no overall greater costs.</p
Additional file 1: of Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections
Details regarding PACTS and Premier data. This additional file provides readers with additional details regarding the Program to Assess Ceftolozane/Tazobactam Susceptibility (PACTS) dataset which was used to provide susceptibility inputs for the model and also regarding the Premier research database which was used to help define the pathogen distribution in cUTI. (DOCX 29 kb
Supplementary materials: Continuous vital sign monitoring in patients after elective abdominal surgery: a retrospective study on clinical outcomes and costs
These are peer-reviewed supplementary materials for the article 'Continuous vital sign monitoring in patients after elective abdominal surgery: a retrospective study on clinical outcomes and costs' published in the Journal of Comparative Effectiveness Research.Table S1: Clinical outcomes in different disease categoriesTable S2: Linear regression results for length of stayTable S3: Logistic regression summary results for ICU admissionTable S4: EWS measurementsTable S5: EWS scores of HR and RR measurementsTable S6: Linear regression summary results for ward costsTable S7: Linear regression summary results for ICU costsTable S8: Linear regression summary results for total costsAim: To assess changes in outcomes and costs upon implementation of continuous vital sign monitoring in postsurgical patients. Materials & methods: Retrospective analysis of clinical outcomes and in-hospital costs compared with a control period. Results: During the intervention period patients were less frequently admitted to the intensive care unit (ICU) (p = 0.004), had shorter length of stay (p Conclusion: Continuous vital sign monitoring may have contributed to fewer ICU admissions and lower ICU costs in postsurgical patients.</p
Additional file 1: of Cost-effectiveness of ceftolozane/tazobactam plus metronidazole versus piperacillin/tazobactam as initial empiric therapy for the treatment of complicated intra-abdominal infections based on pathogen distributions drawn from national surveillance data in the United States
Susceptibility inputs - Program to Assess Ceftolozane/Tazobactam Susceptibility (PACTS) dataset. (DOCX 25 kb